“Ovarian Cancer Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ovarian Cancer Market.
The Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Ovarian Cancer Pipeline Analysis
Some of the key takeaways from the Ovarian Cancer Pipeline Report:
- Ovarian Cancer Companies across the globe are diligently working toward developing novel Ovarian Cancer treatment therapies with a considerable amount of success over the years.
- Ovarian Cancer companies working in the treatment market are Genentech, Sonnet Biotherapeutics, Daiichi Sankyo Company, Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and many others, are developing therapies for the Ovarian Cancer treatment
- Emerging Ovarian Cancer therapies such as Atezolizumab, Tisotumab Vedotin, SON-1010, DS-6000a, and others are expected to have a significant impact on the Ovarian Cancer market in the coming years.
- On April 2024, Bristol-Myers Squibb announced a Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, and Versus Investigator’s Choice Chemotherapy in Women with Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
- On December 2023, Daiichi Sankyo announced a Phase I, Two-Part, Multi-Centre, First-in-Human Study of DS-6000a in Subjects with Advanced Renal Cell Carcinoma and Ovarian Tumors.
- On October 2023, AstraZeneca announced a retrospective observational medical records review study of BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting in France, Italy and the UK. Physicians who treated ovarian cancer patients with olaparib in 1L setting will be requested to recruit patients to have their clinical data abstracted from their clinical records in line with local laws.
Ovarian Cancer Overview
Ovarian cancer arises from abnormal cell growth in the ovaries, often detected at advanced stages due to vague symptoms or lack of effective screening tests. Symptoms may include abdominal pain or bloating, pelvic discomfort, changes in bowel or urinary habits, and feeling full quickly. Risk factors include a family history of ovarian or breast cancer, genetic mutations (such as BRCA1 and BRCA2), increasing age, and certain reproductive factors like never giving birth or early menstruation onset. Diagnosis typically involves pelvic exams, imaging studies (such as ultrasound or MRI), and blood tests measuring tumor markers like CA-125. Treatment may involve surgery to remove the tumor and affected tissue, chemotherapy, and in some cases, targeted therapy or radiation. Prognosis varies based on factors like stage, tumor grade, and response to treatment, with early detection improving outcomes. Research continues to advance understanding and treatment options for ovarian cancer.
Get a Free Sample PDF Report to know more about Ovarian Cancer Pipeline Therapeutic Assessment- Ovarian Cancer Treatment Market
Ovarian Cancer Route of Administration
Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Ovarian Cancer Molecule Type
Ovarian Cancer Products have been categorized under various Molecule types, such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Ovarian Cancer Pipeline Therapeutics Assessment
- Ovarian Cancer Assessment by Product Type
- Ovarian Cancer By Stage and Product Type
- Ovarian Cancer Assessment by Route of Administration
- Ovarian Cancer By Stage and Route of Administration
- Ovarian Cancer Assessment by Molecule Type
- Ovarian Cancer by Stage and Molecule Type
DelveInsight’s Ovarian Cancer Report covers around 200+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Ovarian Cancer product details are provided in the report. Download the Ovarian Cancer pipeline report to learn more about the emerging Ovarian Cancer therapies- Ovarian Cancer Drugs and Therapies
Ovarian Cancer Pipeline Analysis:
The Ovarian Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Ovarian Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer Treatment.
- Ovarian Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ovarian Cancer market.
Download Sample PDF Report to know more about Ovarian Cancer drugs and therapies- Ovarian Cancer Clinical Trials and FDA Approvals
Scope of Ovarian Cancer Pipeline Drug Insight
- Coverage: Global
- Key Ovarian Cancer Companies: Genentech, Sonnet Biotherapeutics, Daiichi Sankyo Company, Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and many others.
- Key Ovarian Cancer Therapies: Atezolizumab, Tisotumab Vedotin, SON-1010, DS-6000a, and others.
- Ovarian Cancer Therapeutic Assessment: Ovarian Cancer current marketed and Ovarian Cancer emerging therapies
- Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers
Request for Sample PDF Report for Ovarian Cancer Pipeline Assessment and clinical trials – Ovarian Cancer Therapeutic Analysis
Table of Contents
1. Ovarian Cancer Report Introduction
2. Ovarian Cancer Executive Summary
3. Ovarian Cancer Overview
4. Ovarian Cancer- Analytical Perspective In-depth Commercial Assessment
5. Ovarian Cancer Pipeline Therapeutics
6. Ovarian Cancer Late Stage Products (Phase II/III)
7. Ovarian Cancer Mid Stage Products (Phase II)
8. Ovarian Cancer Early Stage Products (Phase I)
9. Ovarian Cancer Preclinical Stage Products
10. Ovarian Cancer Therapeutics Assessment
11. Ovarian Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ovarian Cancer Companies
14. Ovarian Cancer Key Products
15. Ovarian Cancer Unmet Needs
16 . Ovarian Cancer Market Drivers and Barriers
17. Ovarian Cancer Future Perspectives and Conclusion
18. Ovarian Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting